The Peanut Allergy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Peanut Allergy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peanut Allergy Market.

Some of the key takeaways from the Peanut Allergy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Peanut Allergy treatment therapies with a considerable amount of success over the years. 
• Peanut Allergy companies working in the treatment market are Allergy Therapeutics, Intrommune Therapeutics, InnoUp Farma, Cour Pharmaceutical, Vedanta Biosciences, Aravax, Prota Therapeutics, AstraZeneca, DBV technologies, Camallergy, Genentech, ALK-Abelló A/S/Syneos Health, DBV Technologies, Aimmune Therapeutics, Inc., Novartis, Alladapt Immunotherapeutics, Inc., and others, are developing therapies for the Peanut Allergy treatment 

• Emerging Peanut Allergy therapies in the different phases of clinical trials are- VLP Peanut, INT301, INP20, CNP-201, VE416, PVX-108, PRT100, Acalabrutini, Viaskin Peanut, CA002, Omalizumab, Peanut SLIT-tablet, DBV712, AR101, Ligelizumab, Remibrutinib, ADP101, and others are expected to have a significant impact on the Peanut Allergy market in the coming years.   
• In September 2022, The phase III VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) clinical trial, which is testing the safety and efficacy of epicutaneous immunotherapy with the modified Viaskin Peanut 250 µg patch in children ages 4-7 years, has been partially clinically suspended by the US Food and Drug Administration (FDA).
• In June 2022, Positive topline results from the Phase III EPITOPE Trial of Viaskin Peanut in Toddlers with Peanut Allergies were released by DBV Technologies. The safety profile of Viaskin Peanut250 μg, which was seen in children with peanut allergy aged 4 and older in previous clinical trials, was largely in line with the EPITOPE safety data.
• In December 2021, The European Medicines Agency (EMA) has been officially informed by DBV Technologies of its decision to withdraw the Marketing Authorization Application (MAA) for Viaskin Peanut.

Peanut Allergy Overview

The majority of severe food-related allergic responses are caused by peanut allergies. It usually manifests early in childhood, and those who are affected rarely outgrow it. Traces of an allergen can cause an allergic reaction in highly sensitized individuals. Ara h1, h2, and h 3 are the main peanut antigens that have been identified by the particular antibody response.

Get a Free Sample PDF Report to know more about Peanut Allergy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight

Emerging Peanut Allergy Drugs Under Different Phases of Clinical Development Include:

• VLP Peanut: Allergy Therapeutics
• INT301: Intrommune Therapeutics
• INP20: InnoUp Farma
• CNP-201: Cour Pharmaceutical
• VE416: Vedanta Biosciences
• PVX-108: Aravax
• PRT100: Prota Therapeutics
• Acalabrutinib: AstraZeneca
• Viaskin Peanut: DBV technologies
• CA002: Camallergy
• Omalizumab: Genentech
• Peanut SLIT-tablet: ALK-Abelló A/S/Syneos Health
• DBV712: DBV Technologies
• AR101: Aimmune Therapeutics, Inc.
• Ligelizumab: Novartis
• Remibrutinib: Novartis
• ADP101: Alladapt Immunotherapeutics, Inc.

Peanut Allergy Route of Administration

Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intradermal
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type 

Peanut Allergy Molecule Type

Peanut Allergy Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type 

Peanut Allergy Pipeline Therapeutics Assessment

• Peanut Allergy Assessment by Product Type
• Peanut Allergy By Stage and Product Type
• Peanut Allergy Assessment by Route of Administration
• Peanut Allergy By Stage and Route of Administration
• Peanut Allergy Assessment by Molecule Type
• Peanut Allergy by Stage and Molecule Type

DelveInsight’s Peanut Allergy Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Peanut Allergy product details are provided in the report. Download the Peanut Allergy pipeline report to learn more about the emerging Peanut Allergy therapies

Some of the key companies in the Peanut Allergy Therapeutics Market include:

Key companies developing therapies for Peanut Allergy are – Vedanta Biosciences, Inc., Allergy Therapeutics, COUR Pharmaceutical Development Company, Inc., ALK-Abelló A/S, Syneos Health, DBV Technologies, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), Alladapt Immunotherapeutics, Inc., and others.

Peanut Allergy Pipeline Analysis:

The Peanut Allergy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peanut Allergy Treatment.
• Peanut Allergy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peanut Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peanut Allergy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peanut Allergy drugs and therapies

Peanut Allergy Pipeline Market Drivers

• Increasing prevalence of peanut allergies, growth in commercial and scientific activities for research and development are some of the important factors that are fueling the Peanut Allergy Market.

Peanut Allergy Pipeline Market Barriers

• However, lack of approved therapies, lack of public awareness of peanut allergy, accurate diagnosis of peanut allergy is critical and other factors are creating obstacles in the Peanut Allergy Market growth.

Scope of Peanut Allergy Pipeline Drug Insight    

• Coverage: Global
• Key Peanut Allergy Companies: Allergy Therapeutics, Intrommune Therapeutics, InnoUp Farma, Cour Pharmaceutical, Vedanta Biosciences, Aravax, Prota Therapeutics, AstraZeneca, DBV technologies, Camallergy, Genentech, ALK-Abelló A/S/Syneos Health, DBV Technologies, Aimmune Therapeutics, Inc., Novartis, Alladapt Immunotherapeutics, Inc., and others
• Key Peanut Allergy Therapies: VLP Peanut, INT301, INP20, CNP-201, VE416, PVX-108, PRT100, Acalabrutini, Viaskin Peanut, CA002, Omalizumab, Peanut SLIT-tablet, DBV712, AR101, Ligelizumab, Remibrutinib, ADP101, and others
• Peanut Allergy Therapeutic Assessment: Peanut Allergy current marketed and Peanut Allergy emerging therapies
• Peanut Allergy Market Dynamics: Peanut Allergy market drivers and Peanut Allergy market barriers 

Request for Sample PDF Report for Peanut Allergy Pipeline Assessment and clinical trials

Table of Contents

1. Peanut Allergy Report Introduction

2. Peanut Allergy Executive Summary

3. Peanut Allergy Overview

4. Peanut Allergy- Analytical Perspective In-depth Commercial Assessment

5. Peanut Allergy Pipeline Therapeutics

6. Peanut Allergy Late Stage Products (Phase II/III)

7. Peanut Allergy Mid Stage Products (Phase II)

8. Peanut Allergy Early Stage Products (Phase I)

9. Peanut Allergy Preclinical Stage Products

10. Peanut Allergy Therapeutics Assessment

11. Peanut Allergy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peanut Allergy Key Companies

14. Peanut Allergy Key Products

15. Peanut Allergy Unmet Needs

16 . Peanut Allergy Market Drivers and Barriers

17. Peanut Allergy Future Perspectives and Conclusion

18. Peanut Allergy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services